Publication:
Effects of sucralose on insulin and glucagon-like peptide-1 secretion in healthy subjects: A randomized, double-blind, placebo-controlled trial

dc.contributor.authorAmornpan Lertriten_US
dc.contributor.authorSasinee Srimachaien_US
dc.contributor.authorSunee Saetungen_US
dc.contributor.authorSuwannee Chanprasertyothinen_US
dc.contributor.authorLa or Chailurkiten_US
dc.contributor.authorChatvara Areevuten_US
dc.contributor.authorPornalat Katekaoen_US
dc.contributor.authorBoonsong Ongphiphadhanakulen_US
dc.contributor.authorChutintorn Sriphrapradangen_US
dc.contributor.otherFaculty of Medicine, Ramathibodi Hospital, Mahidol Universityen_US
dc.date.accessioned2019-08-23T11:37:20Z
dc.date.available2019-08-23T11:37:20Z
dc.date.issued2018-11-01en_US
dc.description.abstract© 2018 Elsevier Inc. Objectives: Emerging evidence shows that non-nutritive sweeteners might induce glucose intolerance. This study aims to determine the effects of chronic exposure to sucralose on glycemic response, insulin secretion and sensitivity, and glucagon-like peptide-1 (GLP-1) release in healthy subjects. Methods: Healthy volunteers who did not use non-nutritive sweeteners and were normoglycemia after oral glucose tolerance test (OGTT) were recruited. Subjects underwent a 75-g OGTT on two separate occasions, preceded by blindly consuming pills containing either 200 mg sucralose or placebo for 4 wk in a randomized crossover trial. Plasma glucose, insulin, and active GLP-1 levels were obtained after ingesting 75-g glucose. On the following day, intravenous glucose tolerance test (IVGTT) was performed to evaluate the acute insulin response (AIR). Results: Fifteen participants (11 females, age 31.9 ± 10 y, body mass index 23.1 ± 3 kg/m2) participated in the study. AIR was lower after exposure to sucralose than placebo (58.9 ± 48.61 versus 69.94 ± 73.81 µU/mL, P < 0.001). Whole-body insulin sensitivity (estimated using the Matsuda index) was lower in sucralose than placebo (4.69 ± 1.67 versus 5.31 ± 2.56, P < 0.005). AUC of active GLP-1 was significantly higher in the sucralose than placebo (23.16 ± 18.86 versus 18.5 ± 22.22 pmol/L ⋅ 120 min, P < 0.001). Conclusions: The continuous exposure to sucralose reduced AIR, decreased insulin sensitivity, and enhanced GLP-1 release in healthy subjects. However, the clinical significance of these results needs to be investigated in longer follow-up studies.en_US
dc.identifier.citationNutrition. Vol.55-56, (2018), 125-130en_US
dc.identifier.doi10.1016/j.nut.2018.04.001en_US
dc.identifier.issn18731244en_US
dc.identifier.issn08999007en_US
dc.identifier.other2-s2.0-85049451401en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/46203
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85049451401&origin=inwarden_US
dc.subjectMedicineen_US
dc.subjectNursingen_US
dc.titleEffects of sucralose on insulin and glucagon-like peptide-1 secretion in healthy subjects: A randomized, double-blind, placebo-controlled trialen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85049451401&origin=inwarden_US

Files

Collections